The comparison of the efficacy of intramuscular tetracosactide and subacromial triamcinolone injection in rotator cuff tendinitis: a randomized trial.

Orandi AH, Mansour A, Bagheri N, Majedi H, Emami Meibodi SA, Pestehei SK, Saberian P

Rheumatology advances in practice20 Dec 2024Cited by 1 (Europe PMC)

PMID39764362PMCIDPMC11703363DOI10.1093/rap/rkae150PepBankPUB-39764362

Summary

ObjectivesRotator cuff tendinitis (RCT) is a tendon inflammation often following subacromial impingement syndrome. One of the non-surgical management modalities for RCT is subacromial injection of corticosteroids. Some studies have claimed a correlation between ACTH (Adrenocorticotropic Hormone) deficiency and rotator cuff lesions; hence, intramuscular ACTH analogue injection has been recommended as an option. This research aimed to compare the effectiveness of these two treatment methods.MethodsWe conducted a study with 86 patients suffering from RCT. The patients were randomly divided into two groups of 43; one group received a subacromial injection of 40 mg of triamcinolone acetonide, while the other group received 1 mg of intramuscular tetracosactide injection. We recorded the Constant-Murley (CM) and visual analogue scale (VAS) scores for each patient before and 4 weeks after injections to measure pain acuity and joint functionality. Later, we compared and analysed the two scores in each group.ResultsBased on the statistical analysis, the mean ages of the participants in the triamcinolone and tetracosactide groups were 53.21 ± 11.37 and 54.56 ± 11.98, respectively. Both groups demonstrated an improvement in VAS for pain and CM scores (P < 0.05). However, the VAS for pain score decreased, and the CM score increased more significantly in the triamcinolone group than in the tetracosactide group (P < 0.05).ConclusionAlthough both treatment methods exhibit promise for pain relief, subacromial injection of triamcinolone appears more efficacious than intramuscular injection of tetracosactide in patients with RCT, based on a 4-week follow-up.Trial registrationIranian Registry of Clinical Trials, https://irct.behdasht.gov.ir, IRCT20240110060673N1.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with rotator cuff tendinitis, tetracosactide produced less VAS pain reduction than triamcinolone (P < 0.05).
In plain wordsIn patients with rotator cuff tendinitis, tetracosactide reduced pain less than triamcinolone.
Peptide
Cosyntropin
Outcome
IncreaseVAS pain score versus triamcinolone
Study
n = 86
Comparator
Subacromial triamcinolone acetonide 40 mg
Outcome group
Pain · Musculoskeletal
Studied dose
1 mg · intramuscularAs given in this study (human).
Source sentences
Summary
However, the VAS for pain score decreased, and the CM score increased more significantly in the triamcinolone group than in the tetracosactide group (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a study with 86 patients suffering from RCT.
Summary · context
The patients were randomly divided into two groups of 43; one group received a subacromial injection of 40 mg of triamcinolone acetonide, while the other group received 1 mg of intramuscular tetracosactide injection.
Summary · context
We recorded the Constant-Murley (CM) and visual analogue scale (VAS) scores for each patient before and 4 weeks after injections to measure pain acuity and joint functionality.
Show in the study text Report a problemFND-3976436203
02HumanRandomized controlled trialEfficacy outcome
In patients with rotator cuff tendinitis, tetracosactide produced less CM score improvement than triamcinolone (P < 0.05).
In plain wordsIn patients with rotator cuff tendinitis, tetracosactide improved joint function less than triamcinolone.
Peptide
Cosyntropin
Outcome
DecreaseConstant-Murley improvement versus triamcinolone
Study
n = 86
Comparator
Subacromial triamcinolone acetonide 40 mg
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 mg · intramuscularAs given in this study (human).
Source sentences
Summary
However, the VAS for pain score decreased, and the CM score increased more significantly in the triamcinolone group than in the tetracosactide group (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a study with 86 patients suffering from RCT.
Summary · context
The patients were randomly divided into two groups of 43; one group received a subacromial injection of 40 mg of triamcinolone acetonide, while the other group received 1 mg of intramuscular tetracosactide injection.
Summary · context
We recorded the Constant-Murley (CM) and visual analogue scale (VAS) scores for each patient before and 4 weeks after injections to measure pain acuity and joint functionality.
Show in the study text Report a problemFND-3976436204
03HumanNon-randomized trialEfficacy outcome
In patients with rotator cuff tendinitis, VAS pain improved after tetracosactide, as in the triamcinolone group (P < 0.05).
In plain wordsIn patients with rotator cuff tendinitis, pain improved from baseline after tetracosactide, as after triamcinolone.
Peptide
Cosyntropin
Outcome
DecreaseVAS pain improvement
Study
n = 43
Outcome group
Pain · Musculoskeletal
Studied dose
1 mg · intramuscularAs given in this study (human).
Source sentences
Summary
Both groups demonstrated an improvement in VAS for pain and CM scores (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a study with 86 patients suffering from RCT.
Summary · context
The patients were randomly divided into two groups of 43; one group received a subacromial injection of 40 mg of triamcinolone acetonide, while the other group received 1 mg of intramuscular tetracosactide injection.
Summary · context
We recorded the Constant-Murley (CM) and visual analogue scale (VAS) scores for each patient before and 4 weeks after injections to measure pain acuity and joint functionality.
Show in the study text Report a problemFND-3976436201
04HumanNon-randomized trialEfficacy outcome
In patients with rotator cuff tendinitis, CM scores improved after tetracosactide, as in the triamcinolone group (P < 0.05).
In plain wordsIn patients with rotator cuff tendinitis, joint function improved from baseline after tetracosactide, as after triamcinolone.
Peptide
Cosyntropin
Outcome
IncreaseConstant-Murley score improvement
Study
n = 43
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 mg · intramuscularAs given in this study (human).
Source sentences
Summary
Both groups demonstrated an improvement in VAS for pain and CM scores (P < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a study with 86 patients suffering from RCT.
Summary · context
The patients were randomly divided into two groups of 43; one group received a subacromial injection of 40 mg of triamcinolone acetonide, while the other group received 1 mg of intramuscular tetracosactide injection.
Summary · context
We recorded the Constant-Murley (CM) and visual analogue scale (VAS) scores for each patient before and 4 weeks after injections to measure pain acuity and joint functionality.
Show in the study text Report a problemFND-3976436202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.